photo walkheader_zpsd5bunpmi.png

Category Archives: Pancreatic Cancer

Adjustments to the FOLFIRINOX Combination for Improved Tolerability in Pancreatic Cancer

Since the May 12, 2011 New England Journal of Medicine article that reported the possible superiority of the 5-FU based four-drug FOLFIRINOX regimen over gemcitabine in the treatment of metastatic pancreatic cancer (ductal adenocarcinoma of the pancreas), researchers have been at work trying to discover the best use of this information – and ways to […]

FOLFIRINOX as Neoadjuvant Therapy for Pancreatic Cancer

The idea behind treating surgically unresectable and borderline resectable pancreatic cancer (ductal adenocarcinoma of the pancreas) with chemotherapy or chemoradiation is that some minority of cases will thereupon improve to the point of now being deemed amenable to surgery, with its typically more favorable outcome.  This is generally the point then of so-called neoadjuvant therapy. […]

Biomarker miR-10b for Pancreatic Cancer: earlier diagnosis and/or therapeutic target?

As alluded to in another recent blog entry, the study of microRNA has been a source of great interest as to the possible development of biomarkers that may screen or aid on the diagnosis of pancreatic cancer (ductal adenocarcinoma of the pancreas).  MicroRNAs (or sometimes abbreviated miR) are small (18 to 25 nucleotide) non-coding RNA […]

Page 17 of 37« First...10...1516171819...30...Last »
Facebook
Facebook